SCHEMBL637236

SCHEMBL637236

O=C(CCCNC(=O)OCOC(=O)c1cccnc1)Oc1ccc(Cl)cc1.[NaH]

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.48
KMT2A Q03164 9/20 0.48
LMNA P02545 5/20 0.48
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 2/20 0.48
USP2 O75604 1/20 0.48
KDM4E B2RXH2 1/20 0.44
MAPT P10636 4/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
ATM Q13315 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
POLB P06746 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19065203 0.99 SMN1; SMN2 (0.49) SMN1; SMN2KMT2ALMNAALDH1A1MEN1
SCHEMBL637671 0.88 TAAR1 (0.47) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL2231331 0.87 TAAR1 (0.48) KMT2AALDH1A1MEN1KDM4EMAPT
SCHEMBL916707 0.82 KMT2A (0.46) SMN1; SMN2KMT2AALDH1A1MEN1MAPT
SCHEMBL637431 0.80 LMNA (0.47) KMT2ALMNAALDH1A1KDM4EMAPT
SCHEMBL636142 0.79 TAAR1 (0.42) SMN1; SMN2KMT2ALMNAALDH1A1MEN1
SCHEMBL917311 0.78 KMT2A (0.42) SMN1; SMN2KMT2AALDH1A1MEN1KDM4E
SCHEMBL917267 0.78 MEN1 (0.46) KMT2ALMNAALDH1A1MEN1MAPT
SCHEMBL638109 0.78 KMT2A (0.44) KMT2ALMNAMEN1L3MBTL1TDP1
SCHEMBL2231742 0.78 TAAR1 (0.43) SMN1; SMN2KMT2ALMNAALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10385014-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use ARBOR PHARMACEUTICALS, LLC (US) 2019-08-20 US disclosed
US-20180258032-A1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE ARBOR PHARMACEUTICALS, LLC 2018-09-13 US disclosed
EP-1660440-B1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE XENOPORT INC (US) 2012-02-22 EP disclosed
EP-2354120-A1 Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof XenoPort, Inc. (US) 2011-08-10 EP disclosed
US-20110021571-A1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE XENOPORT, INC. (US) 2011-01-27 US disclosed
US-20090234138-A1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS XENOPORT, INC. 2009-09-17 US disclosed
US-7572830-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XENOPORT, INC. (US) 2009-08-11 US disclosed
US-20080096960-A1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE XENOPORT, INC. 2008-04-24 US disclosed
US-7300956-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XENOPORT, INC. (US) 2007-11-27 US disclosed
US-20070054945-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XENOPORT, INC. (US) 2007-03-08 US disclosed
US-7109239-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XENOPORT, INC. (US) 2006-09-19 US disclosed
US-20050107334-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use XENOPORT, INC. 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10385014-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use APEH, ABAT, SI SMN1; SMN2 594/4885KMT2A 2442/4885LMNA 3875/4885
US-20180258032-A1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE APEH, ABAT, SI SMN1; SMN2 594/4885KMT2A 2442/4885LMNA 3875/4885
US-20080096960-A1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE APEH, ABAT, SI SMN1; SMN2 594/4885KMT2A 2442/4885LMNA 3875/4885
US-20070054945-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use APEH, ABAT, SI SMN1; SMN2 594/4885KMT2A 2442/4885LMNA 3875/4885
US-20090234138-A1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS APEH, ABAT, GABARAPL1 SMN1; SMN2 377/4885KMT2A 2415/4885LMNA 3907/4885
US-20110021571-A1 ACYLOXYALKYL CARBAMATE PRODRUGS, METHODS OF SYNTHESIS AND USE APEH, ABAT, SI SMN1; SMN2 594/4885KMT2A 2442/4885LMNA 3875/4885
US-20050107334-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis and use APEH, ABAT, SI SMN1; SMN2 594/4885KMT2A 2442/4885LMNA 3875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.